US 11,707,468 B2
Methods of treating pancreatic cancer
Vincent C. O. Njar, Glen Burnie, MD (US); Purushottamachar Puranik, Gaithersburg, MD (US); and Andrew K. Kwegyir-Afful, Severn, MD (US)
Assigned to UNIVERSITY OF MARYLAND, BALTIMORE, Baltimore, MD (US)
Filed by UNIVERSITY OF MARYLAND, BALTIMORE, Baltimore, MD (US)
Filed on Apr. 29, 2020, as Appl. No. 16/861,529.
Application 16/861,529 is a continuation of application No. 15/516,113, granted, now 10,675,289, previously published as PCT/US2015/053653, filed on Oct. 2, 2015.
Claims priority of provisional application 62/058,856, filed on Oct. 2, 2014.
Prior Publication US 2020/0261475 A1, Aug. 20, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/58 (2006.01); C07J 43/00 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); A61K 31/7068 (2006.01)
CPC A61K 31/58 (2013.01) [A61K 31/7068 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07J 43/003 (2013.01)] 14 Claims
 
1. A pharmaceutical composition for treating pancreatic cancer, comprising:
a compound that is at least one selected from the group consisting of

OG Complex Work Unit Chemistry
and a pharmaceutically acceptable salt thereof.